INGREDIENTS
Eptifibatide injection is a clear, colorless, sterile, non-pyrogenic solution for intravenous (IV) use. Each 10 ml vial contains 2 mg/ml of Eptifibatide and each 100 ml vial contains 0.75 mg/ml of Eptifibatide.

CATEGORY
Glycoprotein IIb/IIIa receptor ( GP IIb/IIIa ) antagonist, antiplatelet.

INDICATIONS
Acute Coronary Syndrome
An IV bolus of 180 µg/kg as soon as possible following diagnosis, followed by a continuous infusion of 2.0 µg/kg/min until hospital discharge or initiation of CABG surgery, up to 72 hours. If a patient is to undergo a percutaneous coronary intervention (PCI) while receiving Eptifibatide, the infusion should be continued up to hospital discharge, or for up to 18-24 hours after the procedure, whichever comes first, allowing for up to 96 hours of therapy.

Percutaneous Coronary Intervention (PCI)
An IV bolus of 180 µg/kg administered immediately before the initiation of PCI followed by a continuous infusion of 2.0 µg/kg/min and a second 180 µg/kg bolus 10 minutes after the first bolus. Infusion should be continued until hospital discharge, or for up to 18-24 hours, whichever comes first. A minimum of 12 hours of infusion is recommended.
In patients who undergo coronary artery bypass graft surgery, Eptifibatide infusion should be discontinued prior to surgery.

Disclaimer: Products under patents are offered for sale only in those countries where patents have expired.